12,309 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by Postrock Partners LLC

Postrock Partners LLC acquired a new position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 12,309 shares of the medical research company's stock, valued at approximately $692,000.

Several other hedge funds and other institutional investors have also made changes to their positions in EXAS. Atria Investments Inc acquired a new position in shares of Exact Sciences during the third quarter worth approximately $244,000. Axxcess Wealth Management LLC acquired a new position in shares of Exact Sciences during the third quarter worth approximately $243,000. Harbour Investments Inc. boosted its position in shares of Exact Sciences by 9.2% during the third quarter. Harbour Investments Inc. now owns 29,790 shares of the medical research company's stock worth $2,029,000 after buying an additional 2,518 shares during the period. Huntington National Bank raised its holdings in Exact Sciences by 838.1% during the third quarter. Huntington National Bank now owns 394 shares of the medical research company's stock worth $27,000 after purchasing an additional 352 shares in the last quarter. Finally, Curi RMB Capital LLC raised its holdings in Exact Sciences by 3.2% during the third quarter. Curi RMB Capital LLC now owns 24,468 shares of the medical research company's stock worth $1,667,000 after purchasing an additional 754 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Stock Down 0.6 %

Shares of Exact Sciences stock traded down $0.26 on Tuesday, hitting $44.92. 1,862,641 shares of the company traded hands, compared to its average volume of 2,621,561. The company has a 50-day moving average price of $51.48 and a 200 day moving average price of $58.70. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. Exact Sciences Co. has a 12-month low of $40.62 and a 12-month high of $79.62. The company has a market cap of $8.34 billion, a PE ratio of -8.06 and a beta of 1.25.

Remove Ads

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The business had revenue of $713.42 million for the quarter, compared to analysts' expectations of $701.45 million. Sell-side analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on EXAS. Royal Bank of Canada began coverage on Exact Sciences in a report on Thursday, March 13th. They set a "sector perform" rating and a $52.00 target price on the stock. BTIG Research boosted their target price on Exact Sciences from $65.00 to $75.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. Piper Sandler dropped their target price on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Benchmark reissued a "buy" rating and set a $65.00 target price on shares of Exact Sciences in a report on Monday, January 13th. Finally, TD Cowen boosted their target price on Exact Sciences from $82.00 to $86.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. Two analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Exact Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $70.83.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.